Docetaxel and crocetin co-loaded liposomes for synergistic breast cancer therapy

Puntos clave

• Docetaxel and crocetin combination demonstrates a synergistic effect against breast cancer cells, enhancing therapeutic effectiveness.
• The study utilized co-loaded liposomes to improve drug delivery and bioavailability of both compounds in targeted therapy.
• Results indicated over 50% reduction in tumor growth in the treated group compared to controls, emphasizing the potential benefits of this approach.
• Such findings may highlight the effectiveness of combining multiple agents for better management of breast cancer, warranting further investigation.